FLASCO Fall Session: Advancements in MRD Monitoring Using ctDNA in Lung Cancer
Pharmacy Times
NOVEMBER 3, 2024
Two clinical trials with MRD monitoring may be practice changing: TRACERx and AEGEAN.
Sun.Nov 03, 2024
139 
Novo Nordisk will file semaglutide for MASH next year
pharmaphorum
NOVEMBER 3, 2024
ESSENCE trial of Novo Nordisk's GLP-1 drug semaglutide shows efficacy in MASH, setting up filings in the US and Europe next year
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Weekend ICYMI: October 28 to November 1
Drug Topics
NOVEMBER 3, 2024
In case you missed it, this week we had stories about PBMs' threat to independent pharmacies, the risks and benefits of AI in pharmacy, pharmacists' role in hormonal prescribing, and more.
CMS finalizes 2.9% pay increase for outpatient facilities, ASCs, with new maternal health mandates
Fierce Healthcare
NOVEMBER 3, 2024
Under a final rule issued by the Centers for Medicare and Medicaid Services, outpatient hospital facilities and ambulatory surgical centers will get a 2.9% Medicare pay increase next year, up from | Under a final rule issued by CMS, outpatient hospital facilities and ambulatory surgical centers will get a 2.9% Medicare pay increase next year, up from the 2.6% boost in reimbursement that was floated in the draft rule.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays (Executive Summary)
BioPharm
NOVEMBER 3, 2024
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
As Jurisprudence Under Loper Bright Develops, Early Scorecard is Mixed
The FDA Law Blog
NOVEMBER 3, 2024
By John W.M. Claud & Sara W. Koblitz & JP Ellison — Back in July, the United States Supreme Court turned the world of administrative law on its head, adding new layers of judicial oversight to what might have previously been thought of as fairly non-descript Federal agency functions. One of those cases was Loper Bright v. Raimondo , which formally overruled the 40-year precedent under Chevron , under which courts gave agencies deference when interpreting statutory ambiguity.
Let's personalize your content